Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Should Toot Its Own Horn – Hamburg

This article was originally published in The Tan Sheet

Executive Summary

FDA's food center looks to improve public relations about its work, especially as the agency expects what Commissioner Margaret Hamburg says will be "intense engagement" with Congress.

You may also be interested in...

House FDA Investigation Previews Oversight Shift Under GOP

A congressional investigation into FDA's Puerto Rico district office is an early sign of the scrutiny awaiting the agency under a Republican-dominated House.

Science Board Recommendations Exceed CFSAN's Capabilities - Acheson

FDA's Center for Food Safety and Applied Nutrition is not prepared to do some of the consumer research the agency's Science Board recommends, says David Acheson, the agency's former food chief

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts